Side-by-side · Research reference
CardiogenvsSurvodutide
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-MechanisticHUMAN-REVIEWED5/46 cited
BPhase 3HUMAN-REVIEWED25/54 cited
Cardiogen
Bioregulator · Cardiac
CardiacTissue target
Gene regulationMechanism
AnimalEvidence level
SQ · Variable protocols
Survodutide
GLP-1/Glucagon Dual Agonist · Phase 3
SQ · Once Weekly
01Mechanism of Action
Parameter
Cardiogen
Survodutide
Primary target
Cardiovascular cell gene expressionKhavinson 2022
GLP-1 receptor and glucagon receptor (GCGR)Yathindra 2026Zimmermann 2026
Pathway
Peptide bioregulation → modulation of SASP / inflammaging → cardiac tissue homeostasisKhavinson 2022
Central: CVOs → hypothalamic appetite regulation. Peripheral: GLP-1R → incretin effect; GCGR → hepatic lipid metabolism, energy expenditureZimmermann 2026Long 2026
Downstream effect
Suppression of senescence-associated secretory phenotype (SASP), reduction of age-related inflammatory markers, modulation of heat shock protein expression in cardiac tissue
Decreased energy intake, increased energy expenditure, improved glucose homeostasis, hepatic fat reductionZimmermann 2026Yathindra 2026
Feedback intact?
Presumed — peptide bioregulators act via gene regulation, not receptor agonism
—
Origin
Derived from cardiac tissue peptide extracts; synthetic analogue based on Khavinson bioregulator methodology
—
Antibody development
—
—
02Dosage Protocols
Parameter
Cardiogen
Survodutide
Standard dose
Variable — typically 10–20 mg per course
No standardised human protocol; animal-derived dosing.
Not yet disclosed (Phase 3 ongoing)
SYNCHRONIZE Phase 3 program underway.Rubino 2026
Frequency
Intermittent courses — 10–20 days, repeated periodically
Khavinson-school bioregulators typically dosed as periodic interventions, not continuous.
Once weekly
Evidence basis
Animal models / mechanistic studies
No Phase 1+ human trials in PubMed.
Phase 2 RCT (obesity) · Phase 3 ongoing
Duration
10–20 day courses, repeated 2–4× per year
Russian geriatric protocols; unclear extrapolation to general populations.
—
03Metabolic / Fat Loss Evidence
Parameter
Cardiogen
Survodutide
Primary fat target
—
Total body weight, visceral adipose tissue
Weight loss mechanism
—
Dual action: decreased energy intake + increased energy expenditureZimmermann 2026
Phase 2 efficacy
—
Significant weight loss demonstrated
Specific percentage not disclosed in abstracts.
Metabolic markers
—
Improvements in ALT, AST, LDL levels; significant ALT reduction (MD -22.10 vs placebo)Yathindra 2026Abulehia 2026Andonie 2026
Network meta-analysis
—
Favorable efficacy profile vs other glucagon receptor agonists
Comparative efficacy
—
Network meta-analysis shows competitive efficacy in GRA class
04Side Effects & Safety
Parameter
Cardiogen
Survodutide
Injection site reactions
Mild erythema, induration (presumed)
Expected with subcutaneous administration
Systemic adverse events
No documented serious AEs in available literature
Very limited safety data; no rigorous pharmacovigilance.
—
Immunogenicity
Unknown — no antibody development studies published
—
Long-term safety
Unknown — no extended human trials indexed in PubMed
—
GI symptoms
—
Diarrhea, nausea, fatigue — class effect of GLP-1 agonists
Safety profile
—
Network meta-analysis: comparable safety to other GRAs
Serious adverse events
—
Monitored in Phase 2/3; no unique safety signals reported
Detailed SAE data pending Phase 3 completion.
Glucagon-related effects
—
Potential for tachycardia, increased blood pressure — theoretical glucagon effect
Absolute Contraindications
Cardiogen
- ·Active malignancy (theoretical peptide growth factor concern)
- ·Hypersensitivity to peptide components
Survodutide
- ·Personal or family history of medullary thyroid carcinoma (class effect)
- ·Multiple endocrine neoplasia syndrome type 2
Relative Contraindications
Cardiogen
- ·Acute cardiac events (no safety data in acute MI, unstable angina)
- ·Pregnancy / lactation (no reproductive toxicity data)
Survodutide
- ·Severe GI disease (inflammatory bowel disease, gastroparesis)
- ·History of pancreatitis
- ·Cardiovascular disease (monitor closely for glucagon effects)
05Administration Protocol
Parameter
Cardiogen
Survodutide
1. Reconstitution
Add sterile water or saline per manufacturer instructions (typically 1–2 mL per lyophilised vial). Roll gently to dissolve.
Specific reconstitution protocol not yet publicly disclosed. Follow manufacturer instructions upon approval.
2. Injection site
Subcutaneous — abdomen or thigh. Rotate sites. Use sterile technique.
Subcutaneous — abdomen, thigh, or upper arm. Rotate sites weekly to minimize injection site reactions.
3. Timing
Variable — often evening injection. No established circadian preference.
Once weekly, same day each week. Can be administered at any time of day, with or without meals.
4. Storage
Lyophilised: refrigerate 2–8 °C, protect from light. Reconstituted: use immediately or refrigerate, discard after 7–14 days per labeling.
Store refrigerated (2–8 °C) until use. Do not freeze. Protect from light. Specific reconstituted storage duration pending labeling.
5. Needle
27–30G insulin syringe, 45° angle for subcutaneous administration.
Subcutaneous injection with appropriate gauge needle (typically 27–31G). Use sterile technique.
06Stack Synergy
Cardiogen
+ Thymalin
ModerateKhavinson-school multi-organ bioregulator approach: thymalin (thymic peptide) addresses immune senescence while cardiogen targets cardiac tissue. Combined use in geriatric populations demonstrated normalisation of cardiovascular, endocrine, and immune parameters with reduced mortality over 6–8 years of observation.
- Cardiogen
- 10–20 mg SQ · 10–20 day course
- Thymalin
- 10–30 mg IM · concurrent or sequential courses
- Frequency
- 2–4 courses per year
- Primary benefit
- Multi-system aging mitigation, cardiovascular and immune homeostasis
Survodutide
— no documented stacks